The serine protease HtrA2 cleaves UCH-L1 and inhibits its hydrolase activity: Implication in the UCH-L1-mediated cell death

Biochemical and Biophysical Research Communications

Volumn 415, Issue 1, 2011, Pages 24-29

  Park, Dae Wook ^a   Nam, Min Kyung ^a   Rhim, Hyangshuk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

HtrA2; PD associated genes; Serine protease; Tumor cell death; UCH L1 cleavage; UCH L1 hydrolase inhibition

Indexed keywords

HYDROLASE; HYDROLASE INHIBITOR; LDN 57444; SERINE PROTEINASE OMI; STAUROSPORINE; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1; UCF 101; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN HEK293; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HIGH TEMPERATURE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; MITOCHONDRIAL PROTEINS; PROTEOLYSIS; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; UBIQUITIN THIOLESTERASE;

EID: 80755135496     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.148     Document Type: Article

References (31)

1. Larsen C.N., Price J.S., Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 1996, 35:6735-6744.
2. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., Harada T., Hara Y., Kimura I., Chiba S., Namikawa K., Kiyama H., Noda M., Aoki S., Wada K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 2003, 12:1945-1958.
3. Day I.N., Thompson R.J. UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog. Neurobiol. 2010, 90:327-362.
4. Todi S.V., Paulson H.L. Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci. 2011, 34:370-382.
5. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
6. Hibi K., Westra W.H., Borges M., Goodman S., Sidransky D., Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am. J. Pathol. 1999, 155:711-715.
7. Kim H.J., Kim Y.M., Lim S., Nam Y.K., Jeong J., Lee K.J. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009, 28:117-127.
8. Jang M.J., Baek S.H., Kim J.H. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett. 2011, 302:128-135.
9. Li L., Tao Q., Jin H., van Hasselt A., Poon F.F., Wang X., Zeng M.S., Jia W.H., Zeng Y.X., Chan A.T., Cao Y. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res. 2010, 16:2949-2958.
10. Wang W.J., Li Q.Q., Xu J.D., Cao X.X., Li H.X., Tang F., Chen Q., Yang J.M., Xu Z.D., Liu X.P. Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells. Int. J. Oncol. 2008, 33:1037-1045.
11. Hussain S., Foreman O., Perkins S.L., Witzig T.E., Miles R.R., van Deursen J., Galardy P.J. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 2010, 24:1641-1655.
12. Yu J., Tao Q., Cheung K.F., Jin H., Poon F.F., Wang X., Li H., Cheng Y.Y., Rocken C., Ebert M.P., Chan A.T., Sung J.J. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008, 48:508-518.
13. Bheda A., Shackelford J., Pagano J.S. Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes. PLoS ONE 2009, 4:e6764.
14. Vande Walle L., Lamkanfi M., Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ. 2008, 15:453-460.
15. Pradelli L.A., Beneteau M., Ricci J.E. Mitochondrial control of caspase-dependent and -independent cell death. Cell. Mol. Life Sci. 2010, 67:1589-1597.
16. Srinivasula S.M., Gupta S., Datta P., Zhang Z., Hegde R., Cheong N., Fernandes-Alnemri T., Alnemri E.S. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J. Biol. Chem. 2003, 278:31469-31472.
17. Cilenti L., Soundarapandian M.M., Kyriazis G.A., Stratico V., Singh S., Gupta S., Bonventre J.V., Alnemri E.S., Zervos A.S. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J. Biol. Chem. 2004, 279:50295-50301.
18. Park H.J., Kim S.S., Seong Y.M., Kim K.H., Goo H.G., Yoon E.J., Min do S., Kang S., Rhim H. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J. Biol. Chem. 2006, 281:34277-34287.
19. Kuninaka S., Iida S.I., Hara T., Nomura M., Naoe H., Morisaki T., Nitta M., Arima Y., Mimori T., Yonehara S., Saya H. Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation. Oncogene 2007, 26:2395-2406.
20. Hartkamp J., Carpenter B., Roberts S.G. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol. Cell 2010, 37:159-171.
21. Park H.M., Kim G.Y., Nam M.K., Seong G.H., Han C., Chung K.C., Kang S., Rhim H. The serine protease HtrA2/Omi cleaves Parkin and irreversibly inactivates its E3 ubiquitin ligase activity. Biochem. Biophys. Res. Commun. 2009, 387:537-542.
22. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
23. Li Z., Melandri F., Berdo I., Jansen M., Hunter L., Wright S., Valbrun D., Figueiredo-Pereira M.E. Delta12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochem. Biophys. Res. Commun. 2004, 319:1171-1180.
24. Tan Y.Y., Zhou H.Y., Wang Z.Q., Chen S.D. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor. Mol. Cell. Biochem. 2008, 318:109-115.
25. Das C., Hoang Q.Q., Kreinbring C.A., Luchansky S.J., Meray R.K., Ray S.S., Lansbury P.T., Ringe D., Petsko G.A. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl Acad. Sci. USA 2006, 103:4675-4680.
26. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
27. Chae H.J., Kang J.S., Byun J.O., Han K.S., Kim D.U., Oh S.M., Kim H.M., Chae S.W., Kim H.R. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol. Res. 2000, 42:373-381.
28. Belmokhtar C.A., Hillion J., Segal-Bendirdjian E. Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 2001, 20:3354-3362.
29. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 2010, 11:621-632.
30. Dudek E.J., Lampi K.J., Lampi J.A., Shang F., King J., Wang Y., Taylor A. Ubiquitin proteasome pathway-mediated degradation of proteins: effects due to site-specific substrate deamidation. Invest. Ophthalmol. Vis. Sci. 2010, 51:4164-4173.
31. Cilenti L., Lee Y., Hess S., Srinivasula S., Park K.M., Junqueira D., Davis H., Bonventre J.V., Alnemri E.S., Zervos A.S. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J. Biol. Chem. 2003, 278:11489-11494.